Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

This study is testing a combination of two drugs — HRS-8080 (a hormone-blocking drug) and dalpiciclib (a drug that slows cancer cell growth) — in women with breast cancer that has spread or cannot be removed by surgery. Researchers are evaluating how safe the combination is and how well it works. **You may be eligible if...** - You are a woman aged 18 to 75 - You have hormone receptor-positive (HR+) breast cancer that is advanced or has spread to other parts of the body - You have at least one measurable tumor outside the brain - Your general health is good enough to perform daily activities (ECOG 0-1) - You are expected to live more than 3 months - You are not pregnant or breastfeeding, and are using effective contraception **You may NOT be eligible if...** - Your cancer has spread to internal organs causing serious symptoms - You have already received certain types of treatment that don't meet the study requirements - You have recently had major surgery or certain other cancer drugs Talk to your doctor to see if this trial is right for you.